Replies to post #405519 on Amarin Corp Plc (AMRN)

[shadolane]

The standard of comparison would of course be V.

What each of the generics is the question that doesn't matter.

Regarding the other suggestion that V is maintaining 60% of the market and the generics are fighting for their share of the remaining 40% I'm not sure that the generic aggregate won't take more than 40%.

Can anyone offer why 40% share is a barrier for the generics?